GU Flashcards
Hereditary syndrome associated with urothelial malignancy and gene
HNPCC - MSH2
Treatment of low grade non-muscle invasive bladder cancer
TURBT plus intravesicual mitomycin
Treatment of high grade non-muscle invasive bladder cancer
TURBT plus intravescal BCG with maintenance BCG
Treatment of stage II/III muscle invasive bladder cancer
neoadjuvant platinum based chemo plus radical cystectomy or chemoradiation
Treatment of muscle invasive bladder cancer not amenable to surgery
TURBT + chemoradiation
Management of biopsy without muscle present
re-biopsy
Treatment of platinum resistant bladder cancer
Atezolizumab
Treatment of metastatic bladder cancer
MVAC or Gem/Cis
When is staging necessary in prostate cancer
High tumor grade or PSA
Risk stratification factors in prostate cancer (3)
Stage
Gleasons
PSA
Time for PSA nadir after radiation
1 year
Use of degarelix in prostate cancer
Immediate treatment without 1 week of bicalutimide treatment
Progression in prostate cancer
Imaging growth or 2 or more new lesions
First line treatment of CRPC (2)
abiraterone+pred
enzalutimide
Second line treatment of CRPC (2)
either abiraterone or enzalutimide if not tried
docetaxel + prednisone (especially if aggresive)
Indication for docetaxel in upfront HSPC
High volume viseral disease
More aggressive germ cell hisotology
nonseminoma
Tumor marker for nonseminoma
beta-HCG
Risk factors for seminoma GCT
extrapulmonary metastasis
Risk factors in nonseminoma GCT (2)
extrapulmonary metastasis + elevated serum markers
Indications for neoadjuvant chemo in seminoma
Visceral disease
Chemo regiemens for testicular cancer (3)
BEP, EP, VIP
When to assess tumor markers after orchiectomy
2 weeks
Indications for surveillance only after seminoma orchiectomy
Tumor limited to testis and epididymis with N0 or M0
Long term monitoring for testicular cancer
CXR, physical exam, and tumor markers
Treatment of teratoma
Surgery (chemo resistant)
Familial syndrome associated with clear cell RCC
VHL
Familial syndrome associated with papillary RCC and gene
Hereditary papillary renal carcinoma
c-MET
Size cutoff for nephron sparing surgery
7cm
Indications for treatment with IL-2 in RCC
Clear cell, good performance status, younger
First line therapy for RCC (2)
sunitinib, pazopanib
Second line therapy for RCC (2)
Cabozantinib, axitinib
Indications for metastatectomy for metastatic RCC
solitary lesion only
Poor risk histologic feature in RCC
sarcomatoid
Stauffer syndrome definition
Stauffer syndrome is cytokine-mediated paraneoplastic manifested as nonmetastatic hepatic dysfunction
3 vs 4 cycles of BEP in testicular
Good risk - 3
Intermediate or poor - 4
